Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1B | P49286 | 12/20 | 0.86 |
| ▸ | MTNR1A | P48039 | 6/20 | 0.68 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5871334 | 0.93 | MTNR1B (1.00) | MTNR1BMTNR1A | |
| SCHEMBL8649814 | 0.88 | MTNR1B (1.00) | MTNR1BMTNR1A | |
| SCHEMBL8655497 | 0.87 | MTNR1B (0.79) | MTNR1BMTNR1A | |
| SCHEMBL6422049 | 0.86 | MTNR1B (0.73) | MTNR1BMTNR1A | |
| SCHEMBL8652738 | 0.85 | MTNR1B (0.88) | MTNR1BMTNR1A | |
| SCHEMBL6001623 | 0.85 | MTNR1B (0.70) | MTNR1BMTNR1ASIGMAR1 | |
| SCHEMBL8653594 | 0.85 | MTNR1B (1.00) | MTNR1BMTNR1A | |
| SCHEMBL8652905 | 0.81 | MTNR1B (0.91) | MTNR1BMTNR1A | |
| SCHEMBL8661290 | 0.81 | MTNR1B (0.79) | MTNR1BMTNR1A | |
| SCHEMBL8653620 | 0.81 | MTNR1B (0.91) | MTNR1BMTNR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0745597-A2 | Novel melatonergic indanyl piperazines or homopiperazines | BRISTOL-MYERS SQUIBB COMPANY (US) | 1996-12-04 | — | — | EP | claimed |
| US-7071201-B2 | Serotonin antagonism; muscle relaxant for myotonia; such as 1-(1-(2-(4-methoxyphenyl)ethyl)piperidin-4-yl)-7-methoxy-1,2,3,4 -tetrahydroquinoline | EISAI CO., LTD. (JP) | 2006-07-04 | — | — | US | disclosed |
| US-6579881-B2 | Indoles | EISAI CO., LTD. (JP) | 2003-06-17 | — | — | US | disclosed |
| US-6448243-B1 | SEROTONIN ANTAGONIST FOR TREATING, AMELIORATING AND PREVENTING SPASTIC PARALYSIS OR CENTRAL MUSCLE RELAXANTS FOR AMELIORATING MYOTONIA | EISAI CO., LTD. (JP) | 2002-09-10 | — | — | US | disclosed |
| US-20020086999-A1 | Certain quinoline derivatives | EISAI CO., LTD. | 2002-07-04 | — | — | US | disclosed |
| US-20020019531-A1 | Indoles | EISAI CO., LTD. | 2002-02-14 | — | — | US | disclosed |
| EP-0976732-A1 | 1,4-SUBSTITUTED CYCLIC AMINE DERIVATIVES | Eisai Co., Ltd. (JP) | 2000-02-02 | — | — | EP | disclosed |
| US-5780470-A | TREATING SLEEP DISORDERS AND DEPRESSION | BRISTOL-MYERS SQUIBB COMPANY (US) | 1998-07-14 | — | — | US | disclosed |
| EP-0745597-A2 | Novel melatonergic indanyl piperazines or homopiperazines | BRISTOL-MYERS SQUIBB COMPANY (US) | 1996-12-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020019531-A1 | Indoles | INMT, MUSK, MB | MTNR1B 9/4885MTNR1A 6/4885SIGMAR1 1200/4885 |
| US-20020086999-A1 | Certain quinoline derivatives | CHRM1, CHRNA5, CHRNA4 | MTNR1B 15/4885MTNR1A 12/4885SIGMAR1 523/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.